ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Kyowa Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2020 JPYUSD
Revenue318,352M2,981.70M
Gross Profit227,827M2,133.84M
Operating income55,419M519.05M
Income before tax52,263M489.49M
Net income47,027M440.45M
EBITDA75,885M710.74M
Diluted EPS87.490.81
Dividends Per Share440.41
Total Assets801,290M7,761.05M
Total liabilities102,893M996.59M
Total equity698,396M6,764.45M
Operating cash flow39,502M369.97M
Currency in JPYCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 347,956M 353,380M 271,510M 305,820M 318,352M
Gross Profit 204,610M 215,972M 188,834M 215,129M 227,827M
Operating income 51,468M 62,209M 50,403M 53,354M 55,419M
Income before tax 42,877M 55,849M 66,841M 44,492M 52,263M
Net income 30,450M 42,899M 49,230M 37,674M 47,027M
EBITDA 75,252M 84,241M 66,646M 72,151M 75,885M
Diluted EPS 55.59 78.30 99.29 43.12 87.49
Dividends Per Share 25 27 35 42 44
Total Assets 683,801M 708,295M 741,982M 784,453M 801,290M
Total liabilities 106,766M 92,268M 92,589M 106,203M 102,893M
Total equity 577,036M 616,028M 649,621M 678,250M 698,396M
Operating cash flow 66,881M 64,902M 56,181M 53,655M 39,502M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 3,202.27M 3,151.41M 2,458.37M 2,805.40M 2,981.70M
Gross Profit 1,883.04M 1,926.02M 1,709.78M 1,973.46M 2,133.84M
Operating income 473.66M 554.77M 456.37M 489.43M 519.05M
Income before tax 394.60M 498.05M 605.20M 408.14M 489.49M
Net income 280.23M 382.57M 445.75M 345.59M 440.45M
EBITDA 692.55M 751.25M 603.44M 661.87M 710.74M
Diluted EPS 0.51 0.69 0.89 0.39 0.81
Dividends Per Share 0.23 0.24 0.31 0.38 0.41
Total Assets 5,862.74M 6,287.57M 6,762.81M 7,218.33M 7,761.05M
Total liabilities 915.38M 819.06M 843.90M 977.25M 996.59M
Total equity 4,947.36M 5,468.51M 5,920.98M 6,241.08M 6,764.45M
Operating cash flow 615.51M 578.79M 508.68M 492.19M 369.97M

Valuation Measures

Dec 2020
PER32.13
ROA5.93%
ROE6.83%
Operating margin17.40%
Profit margin14.77%

Key executives

  • President, CEO & Representative Director: Masashi Miyamoto
  • Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
  • Executive Officer, GM-Research & Development: Mitsuo Satoh
  • Representative Director & Executive Vice President: Yutaka Osawa
  • Executive Officer & General Manager-Sales: Hiroshi Sugitani

Shareholders

  • Kirin Holdings Co., Ltd. (53.4%)
  • Nomura Asset Management Co., Ltd. (3.6%)
  • Daiwa Asset Management Co. Ltd. (1.7%)
  • Nikko Asset Management Co., Ltd. (1.6%)
  • Massachusetts Financial Services Co. (1.2%)
  • The Vanguard Group, Inc. (1.1%)
  • BlackRock Fund Advisors (0.8%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
  • Norges Bank Investment Management (0.7%)
  • JPMorgan Asset Management (UK) Ltd. (0.6%)

Contact Details

  • Website:http://www.kyowa-kirin.co.jp
  • Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5205.7200

Related Companies

  • Kyowa Kirin Australia Pty Ltd.
  • Kyowa Kirin Pharma FZ LLC
  • Kyowa Kirin Malaysia Sdn. Bhd.
  • Kyowa Kirin Korea Co., Ltd.
  • Kyowa Kirin Pharma SRL
  • Kyowa Kirin Pharma sro
  • Kyowa Kirin Austria GmbH
  • Kyowa Kirin SARL
  • Kyowa Kirin AB
  • Kyowa Kirin Pharma BV
  • Kyowa Kirin Holdings BV
  • Kyowa Kirin Farmaceutica SL
  • Kyowa Kirin Ireland Ltd.
  • Kyowa Kirin Canada, Inc.
  • Kyowa Kirin Frontier Co., Ltd.
  • Kyowa Medical Promotion Co., Ltd.
  • Kyowa Kirin GmbH
  • Strakan International SARL
  • Kyowa Kirin Plus Co., Ltd.
  • Kyowa Hakko Bio Co. Ltd. (Beijing)
  • Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
  • Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
  • Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
  • Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
  • Kyowa Hakko Kirin (Taiwan) Co. Ltd.
  • Kyowa Hakko Kirin (Singapore) Pte Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin (Thailand) Co. Ltd.
  • ProStrakan SRL
  • Kyowa Hakko Kirin America, Inc.

Competitors

  • Genexine, Inc.
  • Enzychem Lifesciences Corp.
  • FibroGen, Inc.
  • Innate Pharma SA Class A
  • Tetralogic Pharmaceuticals Corporation
  • Adamas Pharmaceuticals, Inc.
  • Seagen, Inc.
  • arGEN-X SE
  • Heron Therapeutics Inc
  • RAPT Therapeutics, Inc.
  • Tonix Pharmaceuticals Holding Corp.
Last Updated on 1 Dec, 2021

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more